331 related articles for article (PubMed ID: 26658418)
1. Multiple Myeloma Gets Three New Drugs.
Poh A
Cancer Discov; 2016 Jan; 6(1):4. PubMed ID: 26658418
[TBL] [Abstract][Full Text] [Related]
2. Oral ixazomib maintenance therapy in multiple myeloma.
Offidani M; Corvatta L; Gentili S; Maracci L; Leoni P
Expert Rev Anticancer Ther; 2016; 16(1):21-32. PubMed ID: 26588946
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
5. Ixazomib - the first oral proteasome inhibitor.
Xie J; Wan N; Liang Z; Zhang T; Jiang J
Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
[TBL] [Abstract][Full Text] [Related]
6. Three new drugs for multiple myeloma.
Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
[No Abstract] [Full Text] [Related]
7. Ixazomib in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
[TBL] [Abstract][Full Text] [Related]
8. Safety of ixazomib for the treatment of multiple myeloma.
Bonnet A; Moreau P
Expert Opin Drug Saf; 2017 Aug; 16(8):973-980. PubMed ID: 28661711
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Laubach JP; Paba Prada CE; Richardson PG; Longo DL
Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
[TBL] [Abstract][Full Text] [Related]
10. Ixazomib: First Global Approval.
Shirley M
Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.
Lonial S
Cancer J; 2016; 22(1):3-6. PubMed ID: 26841009
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
[TBL] [Abstract][Full Text] [Related]
13. Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
Al-Salama ZT; Garnock-Jones KP; Scott LJ
Target Oncol; 2017 Aug; 12(4):535-542. PubMed ID: 28660423
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Salvini M; Troia R; Giudice D; Pautasso C; Boccadoro M; Larocca A
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):91-99. PubMed ID: 29235380
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
16. Elotuzumab for the treatment of multiple myeloma.
Moreau P; Touzeau C
Future Oncol; 2014 May; 10(6):949-56. PubMed ID: 24941981
[TBL] [Abstract][Full Text] [Related]
17. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
[TBL] [Abstract][Full Text] [Related]
18. Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
Zhang K; Desai A; Zeng D; Gong T; Lu P; Wang M
Oncotarget; 2017 Feb; 8(6):10748-10759. PubMed ID: 27863374
[TBL] [Abstract][Full Text] [Related]
19. Second elotuzumab triplet efficacious in MM.
Killock D
Nat Rev Clin Oncol; 2019 Feb; 16(2):67. PubMed ID: 30478425
[No Abstract] [Full Text] [Related]
20. Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Smolewski P; Rydygier D
Expert Opin Investig Drugs; 2019 May; 28(5):421-433. PubMed ID: 30907163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
